🇺🇸 FDA
Pipeline program

AZD0901, Rilvegostomig, DS-8201a

D9804C00001

Phase 2 small_molecule active

Quick answer

AZD0901, Rilvegostomig, DS-8201a for Locally Advanced Resectable Gastroesophageal Adenocarcinoma is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials